Human Pathology
Volume 40, Issue 4 , Pages 527-537 , April 2009

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions

  • Ana Slipicevic, MSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • ,
  • Geir Frode Øy, MSc

      Affiliations

    • Department of Tumor Biology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • ,
  • Inger Cecilie Askildt, BSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • ,
  • Arild Holth, BSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • ,
  • Ellen Hellesylt, BSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • ,
  • Vivi Ann Flørenes, PhD

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N-0310 Oslo, Norway
    • Faculty Division Radiumhospitalet, The Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, Oslo, Norway.

Received 29 July 2008 ,Revised 27 September 2008 ,Accepted 1 October 2008.

References 

  1. Bedrossian CWM. Malignant effusions: a multimodal approach to cytologic diagnosis. New York (NY): Igaku-Shoin; 1994;
  2. Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17:765–775
  3. Banerjee AK, Willetts I, Robertson JF, Blamey RW. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol. 1994;20:33–36
  4. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6:1–12
  5. Guvakova MA. Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol. 2007;39:890–909
  6. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005;16:421–439
  7. Bach LA, Headey SJ, Norton RS. IGF-binding proteins—the pieces are falling into place. Trends Endocrinol Metab. 2005;16:228–234
  8. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824–854
  9. Davidson B, Zhang Z, Kleinberg L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006;12:5944–5950
  10. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405–1412
  11. Sambrook J, Russell DV. Molecular cloning. A laboratory manual. 3rd ed.. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2001;Section 6:4
  12. Tomii K, Tsukuda K, Toyooka S, et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer. 2007;120:566–573
  13. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol. 2004;31:246–254
  14. Davidson B. The biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog. 2007;13:189–227
  15. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001;93:293–308
  16. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol. 1998;22:1203–1214
  17. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–1428
  18. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30:878–882
  19. Davidson B, Baekelandt M, Shih IeM. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol. 2007;35:756–760
  20. Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IeM, Davidson B. The diagnostic role of claudins in serous effusions. Am J Clin Pathol. 2007;127:928–937
  21. Davidson B, Skrede M, Silins I, Shih IeM, Trope' CG, Flørenes VA. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer. 2007;110:1264–1271
  22. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res. 2007;13:1438–1444
  23. Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res. 2005;7:R119–R129
  24. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies—evaluation of five epithelial markers. Virchows Arch. 1999;435:43–49
  25. Le Bouc Y, Bellocq A, Philippe C, et al. Insulin-like growth factors and their binding proteins in pleural fluid. Eur J Endocrinol. 1997;137:467–473
  26. Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16:210–218
  27. Katsaros D, Yu H, Levesque MA, et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer. 2001;37:478–485
  28. Lu L, Katsaros D, Wiley A, et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res. 2006;12:1208–1214
  29. Sayer RA, Lancaster JM, Pittman J, et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol. 2005;96:355–361

☆ This work was supported by grants from the Norwegian Cancer Society (Oslo, Norway), the Health Region of South-Eastern Norway (Hamar, Norway), and the Research Fund at the Norwegian Radium Hospital (Oslo, Norway).

PII: S0046-8177(08)00451-6

doi: 10.1016/j.humpath.2008.10.003

Human Pathology
Volume 40, Issue 4 , Pages 527-537 , April 2009

Article Tools

* Image Usage & Resolution